Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Mutated EGFR-IN-3 is a ATP-competitive and highly selective allosteric dibenzodiazepinone EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) inhibitor(IC50 of 12 nM and 13 nM, respectively. )
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | Inquiry | $ 1,520.00 |
Description | Mutated EGFR-IN-3 is a ATP-competitive and highly selective allosteric dibenzodiazepinone EGFR(L858R/T790M) and EGFR(L858R/T790M/C797S) inhibitor(IC50 of 12 nM and 13 nM, respectively. ) |
Targets&IC50 | EGFRL858R/T790M:12 nM, EGFRC797S:13 nM |
In vitro | Mutated EGFR-IN-3 exhibits antiproliferative activities of a panel of EGFR allosteric inhibitors are 3.2 μM, 2.7 μM, 0.36 μM and 0.20 μM for WT,L858R, L858R/T790M and L858R/T790M/C797S, respectively in the presence of Cetuximab in Ba/F3 cells[1].Mutated EGFR-IN-3 exhibits antiproliferative activities of a panel of EGFR allosteric inhibitors are 7.0 μM, 3.3 μM, 3.8 μM, 4.0 μM and 4.5 μM for parental, WT, L858R, L858R/T790M and L858R/T790M/C797S, respectively in the absence of Cetuximab in Ba/F3 cells[1]. |
Molecular Weight | 508.59 |
Formula | C31H29FN4O2 |
CAS No. | 2375107-27-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Mutated EGFR-IN-3 2375107-27-8 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR Mutated EGFR IN 3 Mutated EGFRIN3 inhibitor inhibit